Copyright
©The Author(s) 2015.
World J Gastroenterol. Apr 7, 2015; 21(13): 3970-3977
Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.3970
Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.3970
Table 4 Tumor responses after treatment of 103 patients
| Parameter | n (%) |
| 16-wk disease-control rate | 50% |
| Best response | |
| Complete response | 0 (0.0) |
| Partial response | 22 (21.4) |
| Stable disease | 58 (56.3) |
| Progressive disease | 23 (22.3) |
| AFP response rate (decrease > 25%) | 39 (37.9) |
| No AFP response rate | 64 (62.1) |
| Change < 25% | 39 (37.9) |
| Increase > 25% | 25 (24.3) |
- Citation: Li JH, Xie XY, Zhang L, Le F, Ge NL, Li LX, Gan YH, Chen Y, Zhang JB, Xue TC, Chen RX, Xia JL, Zhang BH, Ye SL, Wang YH, Ren ZG. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. World J Gastroenterol 2015; 21(13): 3970-3977
- URL: https://www.wjgnet.com/1007-9327/full/v21/i13/3970.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i13.3970